This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month

Viking Therapeutics developed VK2735, a dual GLP-1/GIP receptor agonist, in a clinical trial that showed participants maintained weight loss while taking the drug. The company's stock price increased following the trial results. VK2735 is designed to compete with Eli Lilly's Zepbound, a GLP-1 drug for weight management.

Next story